MATWIN, a wholly owned subsidiary of UNICANCER group (gathering all the French Comprehensive Cancer Centers), is the only national programme dedicated to accelerating early innovation in oncology. Within a few years, this experimental programme that was originally led by the Great South West Canceropole, managed to rally/mobilize an international network of industrial and academic partners severally committed to support innovation in the fight against cancer. Every year, MATWIN offers outreach sessions, training, assessments, coaching and network to optimize oncology French research exposure and attractiveness on a global scale. The whole French ecosystem (major groups, biotechs, canceropoles, TTOs, competitive clusters, incubators, investors, etc.) is involved within MATWIN’s initiative confirming therefore the benefit and added value of this open innovation national action focused on a public health issue.
MATWIN offers to projects leaders applying to the programme (academics or startups) a 3 steps action :
Double international assessment (academic and industrial)
Coaching to optimize projects structuring and industrial development potential
Access to MATWIN’s partners’ network (major groups, biotech, investors) to accelerate projects’ development.
MATWIN’s process relies on a partnership with major international groups involved in oncology (Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Exact Sciences, Gilead, GlaxoSmithKline, Janssen, Nanostring Technologies, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi) that are concerned with sourcing and supporting projects with a high industrial development potential.
From 2009 et 2019 :
And many projects ongoing maturation transfer (TTO, start-up…)